ATE466030T1 - Neues screening-verfahren - Google Patents

Neues screening-verfahren

Info

Publication number
ATE466030T1
ATE466030T1 AT03705107T AT03705107T ATE466030T1 AT E466030 T1 ATE466030 T1 AT E466030T1 AT 03705107 T AT03705107 T AT 03705107T AT 03705107 T AT03705107 T AT 03705107T AT E466030 T1 ATE466030 T1 AT E466030T1
Authority
AT
Austria
Prior art keywords
salt
screening process
new screening
eicosanoid
amino acid
Prior art date
Application number
AT03705107T
Other languages
English (en)
Inventor
Shuji Hinuma
Masaki Hosoya
Yasuaki Ito
Makoto Kobayashi
Hideyuki Tanaka
Shoichi Okubo
Ryo Fujii
Hideki Kizawa
Yuji Kawamata
Kazuhiro Ogi
Masataka Harada
Shoji Fukusumi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE466030T1 publication Critical patent/ATE466030T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03705107T 2002-02-14 2003-02-13 Neues screening-verfahren ATE466030T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002037131 2002-02-14
JP2002204163 2002-07-12
JP2002328696 2002-11-12
JP2003014032 2003-01-22
PCT/JP2003/001483 WO2003068959A1 (fr) 2002-02-14 2003-02-13 Nouveau procede de criblage

Publications (1)

Publication Number Publication Date
ATE466030T1 true ATE466030T1 (de) 2010-05-15

Family

ID=27739281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03705107T ATE466030T1 (de) 2002-02-14 2003-02-13 Neues screening-verfahren

Country Status (6)

Country Link
US (1) US7214495B2 (de)
EP (1) EP1479768B1 (de)
AT (1) ATE466030T1 (de)
AU (1) AU2003211952A1 (de)
DE (1) DE60332320D1 (de)
WO (1) WO2003068959A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
AU2003277576A1 (en) * 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
EP1584925B1 (de) * 2003-01-17 2011-06-01 Takeda Pharmaceutical Company Limited Neues screening-verfahren
WO2005015990A1 (en) * 2003-08-18 2005-02-24 Betagenon Ab New diabetes type 2 animal model
WO2005080412A1 (en) * 2004-02-23 2005-09-01 Theratechnologies Inc Modulators of fatty acid-stimulated insulin secretion and uses thereof
EA011010B1 (ru) 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
WO2005083070A1 (ja) * 2004-03-01 2005-09-09 Pharmadesign, Inc. 血糖値の低下に供される医薬組成物
EP1731505B1 (de) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropansäurederivate
US20060003344A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
AU2006284926A1 (en) * 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Human G protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to MCP-1 expression
US20070122344A1 (en) * 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
WO2007033002A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JP4990789B2 (ja) 2005-11-04 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｇｐｒ４０とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法
US20090313709A1 (en) * 2006-01-31 2009-12-17 Yoshihiko Kaisho Genetically Modified Animal and Use Thereof
CA2646430A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2008030618A1 (en) * 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
CA2662305C (en) * 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
US20080161744A1 (en) 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
US7572934B2 (en) * 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
BRPI0818253A2 (pt) 2007-10-10 2015-04-07 Amgen Inc Moduladores de gpr40 bifenil substituídos
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
EP2285421B1 (de) 2008-05-02 2018-04-11 Novadaq Technologies ULC Verfahren zur herstellung und verwendung substanzbeladener erythrozyten zur beobachtung und behandlung von mikrovaskulärer hämodynamik
JP5551707B2 (ja) * 2008-10-15 2014-07-16 アムジエン・インコーポレーテツド スピロ環ｇｐｒ４０調節因子
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
WO2013190391A2 (en) 2012-06-21 2013-12-27 Novadaq Technologies Inc. Quantification and analysis of angiography and perfusion
EP3201607B1 (de) 2014-09-29 2020-12-30 Novadaq Technologies ULC Bildgebung eines zielfluorophors in einem biologischen material in anwesenheit von autofluoreszenz
CA2963450A1 (en) 2014-10-09 2016-04-14 Novadaq Technologies Inc. Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
JP6931705B2 (ja) 2017-02-10 2021-09-08 ノバダック テクノロジーズ ユーエルシー オープンフィールドハンドヘルド蛍光イメージングシステムおよび方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
GB0031527D0 (en) 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US7241579B2 (en) * 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands

Also Published As

Publication number Publication date
EP1479768A1 (de) 2004-11-24
EP1479768A4 (de) 2006-02-01
WO2003068959A1 (fr) 2003-08-21
US7214495B2 (en) 2007-05-08
EP1479768B1 (de) 2010-04-28
DE60332320D1 (de) 2010-06-10
AU2003211952A1 (en) 2003-09-04
US20050089866A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
ATE466030T1 (de) Neues screening-verfahren
ATE490323T1 (de) Adiponektin-rezeptor und dafür kodierendes gen
WO2002084286A1 (en) Screening method
DE60224536D1 (de) Verfahren zur herstellung von l-aminosäuren unter verwendung von stämmen aus der familie der enterobacteriaceae
DE60322188D1 (de) Zytokin (zcytor17-ligand)
IN2014CN02050A (de)
IS5543A (is) Nýr G próteintengdur viðtaki
ATE511644T1 (de) Neues screening-verfahren
NO20031033D0 (no) Reseptor i EDb-fibronectindomene
WO2003021262A1 (fr) Procede de criblage
ATE494550T1 (de) Neues screening-verfahren
WO2003082320A1 (fr) Nouveau procede de criblage
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
ATE445159T1 (de) Neues screening-verfahren
EP1559721A4 (de) Neue fprl1-liganden und deren verwendung
WO2005100386A3 (en) Canine cold-and menthol-sensitive receptor 1
ATE405579T1 (de) Zwei gonadotropin-freisetzende hormone und methode zur isolierung
WO2003021263A1 (fr) Utilisation d'une proteine de recepteur couple a une proteine g
EP1467207A4 (de) Screening-verfahren
SE9902763D0 (sv) Novel receptor
WO2002061074A1 (fr) Nouvelle proteine et adn la comprenant
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin
WO2002029053A1 (fr) Nouvelle proteine de recepteur couple a la proteine g et adn correspondant

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties